Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
John C. Byrd, Deborah M. Stephens
Publikováno v:
Blood
Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma
Autor:
Pablo Fresia, Jan A. Burger, Catalina Berca, Angimar Uriepero, Javier M. Di Noia, Pablo Elías Morande, Mariela Sivina, Ana Inés Landoni, Pablo Oppezzo, Noé Seija
Publikováno v:
Blood
Activation-induced cytidine deaminase (AID) initiates somatic hypermutation and class switch recombination of the immunoglobulin genes. As a trade-off for its physiological function, AID also contributes to tumor development through its mutagenic act
Autor:
Charles Erlichman, Shaji Kumar, Briant Fruth, Vivek Roy, Jeffrey A. Zonder, Natalie S. Callander, Betsy LaPlant, A. Keith Stewart, Rafael Fonseca, Wee Joo Chng
Publikováno v:
Blood. 125:443-448
Dysregulation of cyclin-dependent kinases is a hallmark of myeloma, and specifically, cdk5 inhibition can enhance the activity of proteasome inhibitors in vitro. Dinaciclib is a novel potent small molecule inhibitor of cyclin-dependent kinases (CDK)1
Autor:
Véronique Leblond, Thérèse Aurran-Schleinitz, Richard Lemal, Mathilde Hunault, Anne Wanquet, Rudy Birsen
Publikováno v:
Blood. 127:2356-2358
To the editor: Central nervous system involvement (CNSi) is a rare complication in chronic lymphocytic leukemia (CLL).[1][1][⇓][2]-[3][3] Neither prognostic factors nor consensual therapeutic management guidelines are available. Multiple therapies
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
Autor:
Martine Amiot, Antonin Papin, Steven Le Gouill, Benoit Tessoulin, Selina Chen-Kiang, Julie Esbelin, Philippe Moreau, David Chiron, Cyrille Touzeau, Catherine Pellat-Deceunynck, Celine Bellanger, Valérie Trichet, Anne Moreau, Christelle Dousset, Sophie Maïga
Publikováno v:
Blood. 128(24)
Mantle cell lymphoma (MCL) accumulates in lymphoid organs, but disseminates early on in extranodal tissues. Although proliferation remains located in lymphoid organs only, suggesting a major role of the tumor ecosystem, few studies have assessed MCL
Autor:
Francis J. Giles, Hagop M Kantarjian, Tianna Dauses, Kathleen M. Murphy, Jeffrey Allebach, Mark J. Levis, B. Douglas Smith, Karin D. Berg, Donald Small, Miloslav Beran
Publikováno v:
Blood. 103:3669-3676
Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutati
Autor:
Wolfram Jung, Peter Staib, Heike Tinnefeld, Paul Scigalla, R. Kuse, Joerg Thomalla, Hubert Serve, Walter Fiedler, Mark Jacobs, Wolfgang E. Berdel, Anne Marie O'Farrell, Oliver G. Ottmann, Ulrich Dührsen, Michael Flasshove, Sonja Loges, Nicoletta Brega, Franco Cavalli, Dieter K. Hossfeld, Rolf M. Mesters
Publikováno v:
Blood. 102:2763-2767
Neoangiogenesis has been shown to play an important role in the pathogenesis of acute myeloid leukemia (AML). Autocrine and paracrine secretion of angiogenic and hematopoietic growth factors such as vascular endothelial growth factor (VEGF) and stem
Autor:
Heather K. Webb, Steven Coutre, Nina D. Wagner-Johnston, Albert S. Yu, Ian W. Flinn, Dave Johnson, Daniel Li, Richard R. Furman, John C. Byrd, Sissy Peterman, Thomas Jahn, Jennifer R. Brown, Don M. Benson, Roger G. Ulrich, Brian J. Lannutti, Celeste M. Bello, Brad S. Kahl, Stephen E. Spurgeon, Langdon L. Miller
Publikováno v:
Blood. 123(22)
In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy
Autor:
Ralph V. Boccia, Dawn E. Pinchasik, Richy Agajanian, Paul Conkling, Amy S. Kimball, Alberto Bessudo, Hui Yang, Wael A. Harb, James R. Berenson
Publikováno v:
Blood. 128:3325-3325
Introduction: Carfilzomib is an irreversible second-generation proteasome inhibitor that is currently approved for the treatment of relapsed or refractory multiple myeloma (MM). The primary objective of the CHAMPION-2 study was to determine the maxim